Switch theme
Sign up to access all valuation multiples
iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.
1992
160
LTM Revenue $75.8M
Last FY EBITDA $22.8M
$686M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
iRadimed has a last 12-month revenue (LTM) of $75.8M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, iRadimed achieved revenue of $73.2M and an EBITDA of $22.8M.
iRadimed expects next 12-month revenue of XXX and NTM EBITDA of XXX
See iRadimed valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $75.8M | XXX | $73.2M | XXX | XXX | XXX |
| Gross Profit | $58.2M | XXX | $56.3M | XXX | XXX | XXX |
| Gross Margin | 77% | XXX | 77% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | $22.8M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 31% | XXX | XXX | XXX |
| EBIT | $23.7M | XXX | $22.0M | XXX | XXX | XXX |
| EBIT Margin | 31% | XXX | 30% | XXX | XXX | XXX |
| Net Profit | $19.7M | XXX | $19.2M | XXX | XXX | XXX |
| Net Margin | 26% | XXX | 26% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, iRadimed's stock price is $58.
iRadimed has current market cap of $737M, and EV of $686M.
See iRadimed trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $686M | $737M | XXX | XXX | XXX | XXX | $1.69 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, iRadimed has market cap of $737M and EV of $686M.
iRadimed's trades at 9.4x EV/Revenue multiple, and 30.1x EV/EBITDA.
Equity research analysts estimate iRadimed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
iRadimed has a P/E ratio of 37.3x.
See valuation multiples for iRadimed and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $737M | XXX | $737M | XXX | XXX | XXX |
| EV (current) | $686M | XXX | $686M | XXX | XXX | XXX |
| EV/Revenue | 9.1x | XXX | 9.4x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 30.1x | XXX | XXX | XXX |
| EV/EBIT | 28.9x | XXX | 31.2x | XXX | XXX | XXX |
| EV/Gross Profit | 11.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 37.3x | XXX | 38.3x | XXX | XXX | XXX |
| EV/FCF | 40.9x | XXX | 40.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialiRadimed's last 12 month revenue growth is 9%
iRadimed's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.
iRadimed's rule of 40 is 41% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
iRadimed's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for iRadimed and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 31% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 41% | XXX | 40% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 21% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 4% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 47% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
iRadimed acquired XXX companies to date.
Last acquisition by iRadimed was XXXXXXXX, XXXXX XXXXX XXXXXX . iRadimed acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was iRadimed founded? | iRadimed was founded in 1992. |
| Where is iRadimed headquartered? | iRadimed is headquartered in United States of America. |
| How many employees does iRadimed have? | As of today, iRadimed has 160 employees. |
| Who is the CEO of iRadimed? | iRadimed's CEO is Mr. Roger Susi. |
| Is iRadimed publicy listed? | Yes, iRadimed is a public company listed on NAS. |
| What is the stock symbol of iRadimed? | iRadimed trades under IRMD ticker. |
| When did iRadimed go public? | iRadimed went public in 2014. |
| Who are competitors of iRadimed? | Similar companies to iRadimed include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of iRadimed? | iRadimed's current market cap is $737M |
| What is the current revenue of iRadimed? | iRadimed's last 12 months revenue is $75.8M. |
| What is the current revenue growth of iRadimed? | iRadimed revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of iRadimed? | Current revenue multiple of iRadimed is 9.1x. |
| Is iRadimed profitable? | Yes, iRadimed is EBITDA-positive (as of the last 12 months). |
| What is the current FCF of iRadimed? | iRadimed's last 12 months FCF is $16.8M. |
| What is iRadimed's FCF margin? | iRadimed's last 12 months FCF margin is 22%. |
| What is the current EV/FCF multiple of iRadimed? | Current FCF multiple of iRadimed is 40.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
